Page 6 - Feidong County News Today : Breaking News, Live Updates & Top Stories | Vimarsana

December 21, 2020 healthcare
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)1 Takeda will receive $322 million USD, subject to customary legal and regulatory closing conditions.
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China. The portfolio generated FY2019 net sales of approximately $109.5 million USD, driven by strong sales of cardiovascular products such as Ebrantil®. While the products included in the sale continue to ....

United States , Ricardo Marek , Ray Capital Management Limited , Takeda Pharmaceutical Company Limited , China To Hasten Biopharmaceutic Co Ltd , Takeda Pharmaceutical Company , Exchange Commission , Asia Pacific To Celltrion Inc , Blackstone Group Inc , White Case , Feidong County , Hefei City , Rare Diseases , Plasma Derived Therapies , Emerging Markets Business Unit , Gray Capital , Costa Saroukos , Chief Financial Officer , Consumer Healthcare Company Limited , Oscara Co , Blackstone Group , Tachosil Fibrin Sealant Patch , Corza Health , Bofa Securities , Pharmaceutical Company Limited , Rare Genetic ,